Biogen (@biogen) header
Biogen (@biogen) profile picture

Official global newsroom account for Biogen, a leading biotech company pioneering innovative science since 1978. Community guidelines: https://nitter.cf/t.co/56frPQHf74

Cambridge, MA
Joined June 2010
Photo by Biogen (@biogen)Photo by Biogen (@biogen)Photo by Biogen (@biogen)Photo by Biogen (@biogen)Photo by Biogen (@biogen)Photo by Biogen (@biogen)Photo by Biogen (@biogen)Photo by Biogen (@biogen)Photo by Biogen (@biogen)Photo by Biogen (@biogen)
#News: Today at #CTAD2026, in partnership with Eisai, we presented analyses of α-synuclein co-pathology from a cerebrospinal fluid (CSF) substudy in an early Alzheimer’s disease trial. Read more: spr.ly/6017ByZ05R
1
3
6
780
#News: New real-world evidence in early Alzheimer’s disease in partnership with Eisai covers treatment pathways, sex-based outcomes and at-home administration. Learn more: spr.ly/6016Byn9sK #CTAD2026
1
3
5
684
#News: Today at #CTAD2026, we shared new two-year results from a Phase 2 study evaluating our investigational therapy targeting tau in early Alzheimer’s disease. Read more: spr.ly/6013Bypo21
1
2
1
8
1,149
#News: Today at #CTAD2026, we presented initial five-year follow-up data in early Alzheimer's disease, including clinical outcomes, disease progression, and safety. Read more: spr.ly/6019Byru0H
3
5
2
21
1,554
We're at @ACRheum (#ACR26) Convergence presenting new data in systemic lupus erythematosus (SLE). Stop by booth #4304 to learn how we aim to develop potential new options for people living with this chronic autoimmune disease.
2
6
778
#News: At the American College of Rheumatology (ACR) Convergence we announced data for an investigational therapy for people living with systemic lupus erythematosus (SLE). Read more: bit.ly/4BW2dTu
1
2
1
3
849
Join us at #ACR26 for a discussion where experts will explore why early conversations about reproductive goals, sustained disease control, and coordinated multidisciplinary care are critical to supporting informed decision-making.
3
612
We’re headed to Atlanta for #ICAR2026, where we’re sharing updates from our ongoing research in Friedreich ataxia (FA). Find us at booth #304 to learn more about the impact of disease progression in people living with FA.
1
1
3
578
We're heading to #BIOEurope! Join our panel discussion to hear insights on advancing innovation, strategic partnerships, and the shifting global landscape. Learn about our partnering opportunities across the globe: spr.ly/6010BHFy1o
1
1
614
We’re headed to #NEI2026 in Colorado Springs! Together with Supernus Pharmaceuticals, we’ll present new real-world evidence on patient-reported outcomes in postpartum depression (PPD). Attending? Visit our medical booth #701 to connect with our team.
1
548
#News: Massachusetts roots, global impact. We’re proud to be in our home state for #CTAD2026, presenting new data from our Alzheimer’s disease portfolio. Read about our upcoming presentations: spr.ly/6010BHmQGY
1
1
596
STARTING SOON: Join our Q3 2026 financial results live webcast at 8:30AM ET. Join here: bit.ly/4svzuAn #Earnings $BIIB
1
3
692
#News: Today we reported our Q3 results, demonstrating that Biogen has returned to growth. Read more: bit.ly/4jKNtQy Forward-looking statements: biogen.com/forward-looking-s… #Earnings $BIIB
2
1
3
755
At @ASNKidney #KidneyWk we’re presenting the latest data across our kidney disease portfolio. Stop by booth #588 and join us at our medical symposiums to learn about our ongoing work to address the unmet needs of this community.
2
3
667
#News: We’re attending @ASNKidney #KidneyWk to share data from our nephrology portfolio. Read more about our upcoming presentations: spr.ly/6012BHR9MG
3
615
#News: Biogen New Ventures is proud to participate in the Series A financing of Estuary Biotherapeutics, a company pioneering targeted gene therapies for autosomal dominant polycystic kidney disease (ADPKD). Learn more: spr.ly/6012BHzBe4
1
1
6
840
#News: Biogen New Ventures is proud to participate in Altay Therapeutics' Series A financing to support the development of an investigational oral therapy for facioscapulohumeral muscular dystrophy (FSHD). Learn more: bit.ly/4s2mBgW
8
879
We’re excited to be at #AAO2026 in New Orleans. Stop by Booth #2419 to learn more about our ongoing work to support people living with geographic atrophy (GA).
1
2
856
#News: Today, we announced long-term 52-week results from a Phase 2 study in people living with cutaneous lupus erythematosus (CLE). Read more: spr.ly/6018BGvbdr
1
2
10
1,230
Find us at the #EADVCongress at booth #2212 to dive into our evolving research in CLE, a serious and chronic autoimmune skin disease that currently has no targeted therapies.
946